GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-04-20| Funding

Forbion Secures $1.48 Billion For Its Newest Funds, With Plans To Grow Biotechs

by Joy Lin
Share To

Life sciences venture capital firm Forbion has announced the raising of €1.35 billion ($1.48 billion) across its two latest funds, bringing the war chest across all of its funds to €3 billion ($3.29 billion). 

Both the Forbion Ventures Fund VI and the Forbion Growth Opportunities Fund II were oversubscribed and broke Forbion’s fundraising records. The funds were secured at the hard cap amount of €750 million ($822 million) and €600 million ($657 million) respectively.

Related article: Forbion Looks to Fund IPO Ambitious Companies With Its €470 Million Fund 

Funding Early and Late-Stage Biotechs  

According to Forbion, Fund VI will go into existing biotechs and new co-founded companies created around assets from pharma or academic institutions, or with established management teams. Forbion has noted that Fund VI enjoyed “a strong re-up rate” by existing investors, and also drew in new investors including Dutch pension funds PME and PMT, and Loyola University Chicago. 

Forbion’s portfolio covers over 30 biotechs, including Amphista Therapeutics, a UK-based targeted protein degradation company, enGene, a Montreal-based gene therapy company in the immune-oncology field, and Pheon Therapeutics, a company focused on developing antibody-drug conjugates for cancer. 

Meanwhile, Growth Opportunities Fund II builds on Forbion’s first Growth Fund. This fund will home in on European biopharmas with late-stage assets, with Forbion aiming to lead funding rounds by injecting up to €70 million ($76.7 million) per deal. The fund has attracted institutional investors including Amundi and Legal & General Capital which will join PME and PMT, Pantheon and Eli Lilly and Company. Forbion has revealed that the fund has already made four investments. 

“We are delighted at the success of these two fundraisings, which were oversubscribed against the backdrop of considerable market uncertainty,” said Robbert van de Griendt, a General Partner in Investor Relations and Impact. 

“The high demand from existing and new institutional and corporate investors reflects their confidence in the strong fundamentals of our industry and in Forbion’s ability to provide capital and expertise that enables high-quality life sciences companies to develop new therapeutics that can significantly impact the future of medicine.”

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Move to Ditch the WHO Again: Day 1 Sees a Slew of Executive Orders Signed Off
2025-01-21
Sen-Jam’s First-in-Class FDA-Regulated Hangover Cure Enters Phase 2 Trials
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top